Name: Anti-Integrin beta 3 antibody [ERP17507]
Brand: RabMAb
SKU: ab179473

Product name

Anti-Integrin beta 3 antibody [ERP17507]
See all Integrin beta 3 primary antibodies
Description

Rabbit monoclonal [ERP17507] to Integrin beta 3
Host species

Rabbit
Tested applications

Suitable for: WB, IHC-P, IPmore details
Species reactivity

Reacts with: Human
Immunogen

Recombinant fragment within Human Integrin alpha V beta 3 aa 100-400. The exact sequence is proprietary.
Database link: P05106

Run BLAST with Run BLAST with
Positive control
- WB: HT-29, HEK-293, HUVEC, HeLa and HEL 92.1.7 whole cell lysates; Human spleen lysate; Human plasma. IHC-P: Human spleen, osteosarcomas and thyroid cancer tissues. IP: HeLa whole cell lysate.
General notes

Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab^® patents.
This product is a recombinant rabbit monoclonal antibody.

Form

Liquid
Storage instructions

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage buffer

Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
Purity

Protein A purified
Clonality

Monoclonal
Clone number

ERP17507
Isotype

IgG
Research areas

Alternative Versions
- Anti-Integrin beta 3 antibody [ERP17507] - BSA and Azide free (ab240214)
Compatible Secondaries
- Goat Anti-Rabbit IgG H&L (HRP) (ab97051)
Isotype control
- Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730)
Related Products
- VeriBlot for IP Detection Reagent (HRP) (ab131366)

Our Abpromise guarantee covers the use of ab179473 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB		1/1000. Detects a band of approximately 130, 97 kDa (predicted molecular weight: 87 kDa).
IHC-P		1/800. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
IP		1/40.

Function

Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Tissue specificity

Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.
Involvement in disease

Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.
Sequence similarities

Belongs to the integrin beta chain family.
Contains 1 VWFA domain.
Post-translational
modifications

Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding.
Cellular localization

Membrane.
Target information above from: UniProt accession P05106 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
Database links
- Entrez Gene: 3690 Human
- Omim: 173470 Human
- SwissProt: P05106 Human
- Unigene: 218040 Human
Alternative names
- BDPLT16 antibody
- BDPLT2 antibody
- CD 61 antibody
- CD61 antibody
- CD61 antigen antibody
- GP3A antibody
- GPIIIa antibody
- GT antibody
- HPA 1 antibody
- HPA 4 antibody
- Integrin beta 3 (platelet glycoprotein IIIa antigen CD61) antibody
- Integrin beta chain beta 3 antibody
- Integrin beta-3 antibody
- ITB3_HUMAN antibody
- ITG B3 antibody
- ITGB 3 antibody
- ITGB3 antibody
- NAIT antibody
- Platelet fibrinogen receptor beta subunit antibody
- Platelet fibrinogen receptor, beta subunit antibody
- Platelet glycoprotein IIIa antibody
- Platelet glycoprotein IIIa precursor antibody
- Platelet membrane glycoprotein IIIa antibody
- PTP antibody
see all

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Immunohistochemical analysis of paraffin-embedded Human spleen tissue labeling Integrin beta 3 with ab179473 at 1/800 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Positive staining on platelets (PMID: 25356112) of Human spleen is observed.

Counter stained with Hematoxylin.

Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.
Western blot - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

All lanes : Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/500 dilution

Lane 1 : U-87MG (Human glioblastoma-astrocytoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 2 : HEL (Human Erythroleukemia erythroblast) whole cell lysates with 5% NFDM/TBST
Lane 3 : LnCaP (Human prostate carcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 4 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 5 : HUVEC (Human umbilical vein endothelial cell) whole cell lysates with 5% NFDM/TBST
Lane 6 : PC-3 (Human prostate adenocarcinoma epithelial cell) whole cell lysates with 5% NFDM/TBST
Lane 7 : C2C12 (Mouse myoblasts myoblast) whole cell lysates with 5% NFDM/TBST
Lane 8 : Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysates with 5% NFDM/TBST
Lane 9 : Mouse brain lysates with 5% NFDM/TBST

Lysates/proteins at 20 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

Predicted band size: 87 kDa
Observed band size: 110 kDa
why is the actual band size different from the predicted?

Exposure time: 10 seconds

LnCaP, HeLa and PC-3 are low expression controls. This product doesn’t react with Ms
Western blot - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

All lanes : Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/1000 dilution

Lane 1 : HT-29 (Human colorectal adenocarcinoma cell line) whole cell lysate
Lane 2 : HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate
Lane 3 : Human spleen lysate

Lysates/proteins at 20 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 87 kDa
Observed band size: 130,97 kDa why is the actual band size different from the predicted?

Exposure time: 15 seconds

Blocking/Dilution buffer: 5% NFDM/TBST.

The molecular weight observed is consistent with the description in the literature (PMID: 1710517).
Western blot - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

All lanes : Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/1000 dilution

Lane 1 : HUVEC (Human umbilical vein endothelial cell line) whole cell lysate
Lane 2 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate

Lysates/proteins at 20 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 87 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted?

Exposure time: 10 seconds

Blocking/Dilution buffer: 5% NFDM/TBST.

The molecular weight observed is consistent with the description in the literature (PMID: 1710517).
Western blot - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1000 cells + HEL 92.1.7 (Human bone marrow erythroleukemia cell line) whole cell lysate at 10 µg

Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 87 kDa
Observed band size: 97 kDa why is the actual band size different from the predicted?

Exposure time: 5 seconds

Blocking/Dilution buffer: 5% NFDM/TBST.

The molecular weight observed is consistent with the description in the literature (PMID: 1710517).
Western blot - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/5000 dilution + Human plasma at 10 µg

Secondary
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 87 kDa
Observed band size: 97 kDa why is the actual band size different from the predicted?

Exposure time: 3 minutes

Blocking/Dilution buffer: 5% NFDM/TBST.

The molecular weight observed is consistent with the description in the literature (PMID: 1710517).
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Immunohistochemical analysis of paraffin-embedded Human osteosarcomas tissue labeling Integrin beta 3 with ab179473 at 1/800 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Membrane staining on cells of Human osteosarcomas is observed; several multinucleated osteoclasts are positively stained (PMID: 15692727; PMID: 25534583).

Counter stained with Hematoxylin.

Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Immunohistochemical analysis of paraffin-embedded Human thyroid cancer tissue labeling Integrin beta 3 with ab179473 at 1/800 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Membrane or cytoplasmic staining on tumor cells of Human thyroid cancer is observed.

Counter stained with Hematoxylin.

Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.
Immunoprecipitation - Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Integrin beta 3 was immunoprecipitated from 1mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate with ab179473 at 1/40 dilution.

Western blot was performed from the immunoprecipitate using ab179473 at 1/1000 dilution.

VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.

Lane 1: HeLa whole cell lysate, 10µg (Input).

Lane 2: ab179473 IP in HeLa whole cell lysate.

Lane 3: Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) instead of ab179473 in HeLa whole cell lysate.

Blocking and dilution buffer and concentration: 5% NFDM/TBST.

Exposure time: 3 seconds.

Western blot protocols
Immunoprecipitation protocols
Immunohistochemistry protocols

Datasheet

This product has been referenced in:

Kazmierczak PM et al. Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma. PLoS One 13:e0204930 (2018). Read more (PubMed: 30281669) »

See 1 Publication for this product

Publishing research using ab179473? Please let us know so that we can cite the reference in this datasheet.

Location selector

Your location is currently set to:

Custom solutions & partnerships

Recombinant Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Overview

Properties

Associated products

Applications

Target

Images

Protocols

Datasheets and documents

References

This product has been referenced in:

Customer reviews and Q&As